Year: 2017
Type: dissertation
Abstract: To examine the response of the metabolic phenotype to diabetes and antidiabetic medication is of great importance in drug discovery and patient therapy, since it allows the determination of new drug targets and improves the understanding of the underling drug mechanisms.Pathological processes as well as action of a drug, affect organs in a site specific manner.Therefore, technologies offering the detection and monitoring of the metabolic response from specific body regions or organs are required.Here mass spectrometry based metabolomics is the tool of choice as it allows the simultaneously and sensitive tracing of numerous metabolites, and their change in response to pharmacological interventions.In this work, metabolomics were used to study antidiabetic drug action in peripheral organs (testis, lung, adrenal gland, cerebellum) and on the systemic level (plasma).The obtained data can extend the present knowledge about standard and novel therapeutic intervention in the field of diabetes care.Three different antidiabetic therapies were applied to a diabetic mouse model.Two single drugs (metformin, SGLT2-inhibitor), and a combination of both drugs were administered.Each treatment was administered as one single dose, or as repeated daily administration over 14 days.Subsequently, the metaboloic response to the acute and sub-chronic antidiabetic intervention was investigated.All measured metabolites and treatment groups underwent strict statistical evaluation, using a linear model and applying outlier control and correction for multiple testing to exclude artifacts.The utilization of ratios between metabolite concentrations dramatically reduces the noise in the data set.Furthermore, metabolite ratios enable the detection of correlations between metabolites, which were not detectable for the single metabolites.This allows the investigation of biochemical pathways.During the acute antidiabetic intervention, SGLT2-inhibitor treatment had the greatest impact on metabolism.Most alterations were found for amino acids and acylcarnitines.These metabolic alterations were similar to those observed during fasting.It was hypothesized that a long-term intervention with SGLT2-inhibitor can mimic the effects of fasting and therefore led to a normalization of diabetes related factors.During the sub-chronic intervention, metformin was mainly the cause of action for the observed metabolic alteration.However, metformin treatment alone failed to normalize blood glucose levels.This was only reached during combination treatment with both antidiabetic drugs.The metabolomics patterns for metformin and combination treatment are similar to each other.However, the combination Trp Tryptophan Tyr Tyrosine Val Valine MetabolomicsDiabetes and the metabolic syndrome are disorders of the metabolism.The characterization of the occurring metabolic changes is the key for understanding the molecular mechanisms behind them.Metabolomics is one of the tools to answer this question and has already shown its power in diabetes research in several studies [51], [52].Metabolomics aims to identify and quantify the total assemblage of small molecules (<1500 Da) in a biological sample.Therefore, metabolomics tries to cover the sum of all biochemical processes in living organisms.Even if the high-throughput analysis of hundreds of metabolites is a relative new
Author: Sven Zukunft
Institution: Technical University of Munich
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: antidiabetic drugs, metformin, SGLT2 inhibitors, diabetes mellitus, drug combination therapy, metabolic response, amino acids, acylcarnitines, tryptophan metabolism, tyrosine metabolism, valine metabolism, plasma metabolites, organ-specific metabolism, diabetic mouse model, drug mechanisms, metabolic syndrome, blood glucose normalization, mass spectrometry
Open Access status: green
OpenAlex ID: W2748510929
